医学
肾小球疾病
肾脏疾病
局灶节段性肾小球硬化
膜性肾病
肥胖
内科学
糖尿病肾病
肾病
脂肪组织
生物标志物
蛋白尿
肾小球硬化
疾病
内分泌学
肾
病理
糖尿病
肾小球肾炎
蛋白尿
生物
生物化学
作者
Aiko P. J. de Vries,Piero Ruggenenti,Xiong Z. Ruan,Manuel Praga,Josep M. Cruzado,Ingeborg M. Bajema,Vivette D. D’Agati,Hildo J. Lamb,Draženka Pongrac Barlovič,Radovan Hojs,Manuela Abbate,Rosa Rodriquez,Carl Erik Mogensen,Esteban Porrini
标识
DOI:10.1016/s2213-8587(14)70065-8
摘要
The global increase in chronic kidney disease (CKD) parallels the obesity epidemic. Obesity conveys a gradual but independent risk of progression of CKD that seems irrespective of the underlying nephropathy. Obesity has been associated with a secondary focal segmental glomerulosclerosis coined obesity-related glomerulopathy (ORG). Pathways through which obesity might cause renal disease are not well understood, and early clinical biomarkers for incipient ORG or renal relevant obesity are currently lacking. Recent human and experimental studies have associated ectopic lipid accumulation in the kidney (fatty kidney) with obesity-related renal disease. There is enough growing insight that ectopic lipid—the accumulation of lipid in non-adipose tissue—is associated with structural and functional changes of mesangial cells, podocytes, and proximal tubular cells to propose the development of ORG as a maladaptive response to hyperfiltration and albuminuria. Recent advances in metabolic imaging might validate ectopic lipid as a biomarker and research aid, to help translate novel therapeutics from experimental models to patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI